2.150USDMkt Cap: 91.47M USDP/E: —Last update: 2026-05-21
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's dise…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap91.47M USD
Enterprise Value47.14M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.85M USD
Revenue/Share—
Last Price2.150 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS03615A1088
Valuation
P/E (Trailing)—
P/E (Forward)-1.58
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B19.55
EPS (TTM)-1.71
EPS (Forward)-1.36
52W Range
1.91480% of range2.210
52W High2.210 USD
52W Low1.914 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-171.23%
ROA-136.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.62M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-14.22M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio1.27
Quick Ratio1.11
Book Value/Sh0.1100 USD
Cash/Share0.4980 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.50 USD
Target Range8.000 USD – 17.00 USD
# Analysts2
Ownership
Shares Out.42.54M
Float24.58M
Insiders13.88%
Institutions16.77%
Short Interest
Short Ratio3.7d
Short % Float15.61%
Short % Out.13.90%
Shares Short4.82M
Short (prev mo.)3.23M
Technical
SMA 502.132 (+0.8%)
SMA 2002.630 (-18.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.20M
Avg Vol (10d)1.17M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—